BREAST CANCER

Pat Whitworth, MD, discusses how surgeons remain involved in genetic counseling to meet the immense unmet need that exists for patients with breast cancer.

Treatment with trastuzumab (Herceptin) has shown such a benefit in the treatment of patients with HER2-positive breast cancer that it is now the standard of care despite its association with cardiotoxicity. As such, researchers have taken to searching for ways to lessen or prevent the incidence of cardiac events in trials with trastuzumab. 

Adam M. Brufsky, MD, PhD, discusses considerations for using denosumab as well as zoledronic acid as in patients with breast cancer.

The addition of the CDK4/6 inhibitor ribociclib to frontline letrozole reduced the risk of disease progression or death by 40% in elderly patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the link between circulating tumor cells and survival outcomes in metastatic breast cancer.

Sheldon M. Feldman, MD, has been named chief of the Division of Breast Surgery and Surgical Oncology, and director of Breast Cancer Services at Montefiore Einstein Center for Cancer Care at the Albert Einstein College of Medicine, Montefiore has announced. He will also join the faculty of Albert Einstein College of Medicine as a professor of clinical surgery.

The addition of pertuzumab to trastuzumab and chemotherapy reduced the risk of recurrence of invasive disease or death in patients with HER2-positive early breast cancer in the phase III APHINITY study.

John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant versus anastrozole in patients with HR-positive advanced breast cancer.

Lisa Carey, MD, discusses the current state of the science in TNBC, the potential for immunotherapy, and future treatment approaches she anticipates in the coming years.

PFS was improved with Olaparib versus standard chemotherapy in patients with <em>BRCA</em>-positive, HER2-negative breast cancer, according to findings from the phase III OLYMPIAD trial.

Breast cancer is a leading cause of cancer death in women, with 12% to 20% of cases classified as triple-negative breast cancer.

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses a study of cobimetinib plus paclitaxel in triple-negative breast cancer (TNBC).

The treatment of TNBC continues to be a challenge for physicians because of its limited treatment options, the dearth of approved targeted therapies, high mortality, and poor prognosis.

Breast cancer is a leading cause of cancer death in women, with 12% to 20% of cases classified as triple-negative breast cancer.

An axillary lymph node dissection can be avoided for patients with large, operable tumors in the breast, no clinical signs of cancer in the axillary nodes before being treated with neoadjuvant chemotherapy, and no signs of cancer following a sentinel lymph node biopsy during surgery.

Welela Tereffe, MD, discusses&nbsp;the current state of RT in breast cancer and emphasized the importance of a multidisciplinary approach.

According to the results of a study recently published in <em>JAMA Oncology,</em>&nbsp;high breast density surpasses other known risk factors for developing breast cancer, including family history of the disease, personal history of benign lesions, and later-in-life childbirth.

Melanie E. Royce, MD, PhD,&nbsp;discusses the recent progress in the landscape of HER2-positive breast cancer and what she envisions future treatment approaches will be for patients.&nbsp;

Joyce A. O&rsquo;Shaughnessy, MD, addresses some of the key issues in breast cancer and shared her expert insight on where TNBC treatment is headed based on recent findings.

A prospective study is looking at whether breast cancer surgery can be eliminated in patients who respond well to neoadjuvant systemic therapy.

Measuring molecular biomarkers after metastasis could inform treatment decisions for women with breast cancer that has spread to the brain.

A pre-planned subgroup analysis of data from the MONALEESA-2 trial demonstrated similar clinical benefit and safety profiles in elderly patients compared to younger patients with HR+/HER2-advanced breast cancer, supporting a paradigm shift in the future medical management of these patients from the current standard of letrozole to combined treatment of letrozole plus ribociclib.

Yu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer.&nbsp;

Adam M. Brufsky, MD, PhD, discusses combining cobimetinib and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer.

Jenny C. Chang, MD, speaks about the significance of molecular testing in breast cancer and how it will lead to an improvement in treatment approaches in 2017 and beyond.

The risk of progression or death was reduced by 40% with the&nbsp;combination of nab-paclitaxel and carboplatin compared with 2 other chemotherapy doublets as a frontline therapy for patients with metastatic triple-negative breast cancer.

Alberto Montero, MD, discusses the significance of the PERTAIN study in estrogen-positive, HER2-positive patients.

Sarah Hurvitz, MD, gives an overview of the neoMONARCH trial in hormone receptor-positive, HER2-negative breast cancer.

Neoadjuvant chemotherapy with nanoparticle albumin-bound nab-paclitaxel has demonstrated substantial activity across major subgroups of breast cancer, a meta-analysis of clinical trials showed.